XmAb808 promoted IFNγ release from T cells and IL2-mediated expansion of T cells with enhanced survival, translating to increased T cell–mediated killing of cancer cells in vitro but only in the presence of both Signal 1 and B7-H3+ target cells. Here, IL2 is linked to cancer.